Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
SYBX

SYBX - Synlogic Inc Stock Price, Fair Value and News

$0.61+0.01 (+1.67%)
Market Closed

38/100

SYBX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

38/100

SYBX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.98

Target 3M

$1.08

Target 6M

$1.04

SYBX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SYBX Price Action

Last 7 days

-1.6%

Last 30 days

-47.4%

Last 90 days

-64.3%

Trailing 12 Months

-56.7%

SYBX RSI Chart

SYBX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

SYBX Valuation

Market Cap

7.1M

Price/Earnings (Trailing)

-2.21

Price/Sales (Trailing)

7.12

EV/EBITDA

2.28

Price/Free Cashflow

-1.78

SYBX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.98

Target 3M

$1.08

Target 6M

$1.04

SYBX Fundamentals

SYBX Revenue

Revenue (TTM)

2.8M

Rev. Growth (Yr)

-31.1%

Rev. Growth (Qtr)

-3.31%

SYBX Earnings

Earnings (TTM)

-3.2M

Earnings Growth (Yr)

-1.9K%

Earnings Growth (Qtr)

-334.97%

SYBX Profitability

EBT Margin

-131.79%

Return on Equity

-31.25%

Return on Assets

-19.49%

Free Cashflow Yield

-56.11%

SYBX Investor Care

Shares Dilution (1Y)

0.02%

Diluted EPS (TTM)

-0.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20243.3M3.1M2.8M0
20231.7M2.2M2.3M3.4M
20221.8M1.7M1.2M1.2M
2021854.8K1.2M1.5M1.8M
20202.5M2.5M2.4M545.0K
20192.5M2.6M1.1M2.2M
20182.7M830.0K2.5M2.5M
2017444.0K2.4M2.4M2.4M
2016000444.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Synlogic Inc

SYBX
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat solid tumors and lymphoma. It has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
 CEO
 WEBSITEsynlogictx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES72

Synlogic Inc Frequently Asked Questions

SYBX is the stock ticker symbol of Synlogic Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Synlogic Inc is 7.14 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check SYBX's fair value in chart for subscribers.

The fair value guage provides a quick view whether SYBX is over valued or under valued. Whether Synlogic Inc is cheap or expensive depends on the assumptions which impact Synlogic Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SYBX.

As of Wed Jan 28 2026, SYBX's PE ratio (Price to Earnings) is -2.21 and Price to Sales (PS) ratio is 7.12. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SYBX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Synlogic Inc has provided -0.326 (multiply by 100 for percentage) rate of return.